These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 34856350)

  • 1. Design, synthesis, structural optimization, SAR, in silico prediction of physicochemical properties and pharmacological evaluation of novel & potent thiazolo[4,5-d]pyrimidine corticotropin releasing factor (CRF) receptor antagonists.
    Islam MR; Teleb M; Karageorgos V; Sakellaris S; Papadopoulos M; Pirmettis I; Fronczek FR; Liapakis G; Fahmy H
    Eur J Pharm Sci; 2022 Feb; 169():106084. PubMed ID: 34856350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, Synthesis, and Biological Evaluations of Novel Thiazolo[4,5-d]pyrimidine Corticotropin Releasing Factor (CRF) Receptor Antagonists as Potential Treatments for Stress Related Disorders and Congenital Adrenal Hyperplasia (CAH).
    Islam MR; Markatos C; Pirmettis I; Papadopoulos M; Karageorgos V; Liapakis G; Fahmy H
    Molecules; 2024 Aug; 29(15):. PubMed ID: 39125051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis of substituted pyrimidines as corticotropin releasing factor (CRF) receptor ligands.
    Kuppast B; Spyridaki K; Liapakis G; Fahmy H
    Eur J Med Chem; 2014 May; 78():1-9. PubMed ID: 24675175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis of 2-imino and 2-hydrazono thiazolo[4,5-d]pyrimidines as corticotropin releasing factor (CRF) antagonists.
    Teleb M; Kuppast B; Spyridaki K; Liapakis G; Fahmy H
    Eur J Med Chem; 2017 Sep; 138():900-908. PubMed ID: 28750312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis of new thiazolo[4,5-d]pyrimidines as Corticotropin releasing factor modulators.
    Kuppast B; Spyridaki K; Lynch C; Hu Y; Liapakis G; Davies GE; Fahmy H
    Med Chem; 2014; 11(1):50-9. PubMed ID: 25059547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances with the CRF1 receptor: design of small molecule inhibitors, receptor subtypes and clinical indications.
    McCarthy JR; Heinrichs SC; Grigoriadis DE
    Curr Pharm Des; 1999 May; 5(5):289-315. PubMed ID: 10213797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Don't stress about CRF: assessing the translational failures of CRF
    Spierling SR; Zorrilla EP
    Psychopharmacology (Berl); 2017 May; 234(9-10):1467-1481. PubMed ID: 28265716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure and function of the ovine type 1 corticotropin releasing factor receptor (CRF1) and a carboxyl-terminal variant.
    Myers DA; Trinh JV; Myers TR
    Mol Cell Endocrinol; 1998 Sep; 144(1-2):21-35. PubMed ID: 9863624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design of 2,5-dimethyl-3-(6-dimethyl-4-methylpyridin-3-yl)-7-dipropylaminopyrazolo[1,5-a]pyrimidine (NBI 30775/R121919) and structure--activity relationships of a series of potent and orally active corticotropin-releasing factor receptor antagonists.
    Chen C; Wilcoxen KM; Huang CQ; Xie YF; McCarthy JR; Webb TR; Zhu YF; Saunders J; Liu XJ; Chen TK; Bozigian H; Grigoriadis DE
    J Med Chem; 2004 Sep; 47(19):4787-98. PubMed ID: 15341493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The blockade of corticotropin-releasing factor 1 receptor attenuates anxiety-related symptoms and hypothalamus-pituitary-adrenal axis reactivity in mice with mild traumatic brain injury.
    Kosari-Nasab M; Sadeghi T; Bashiri H; Shokouhi G; Salari AA
    Behav Pharmacol; 2019 Apr; 30(2 and 3-Spec Issue):220-228. PubMed ID: 30883392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-peptidic CRF1 receptor antagonists for the treatment of anxiety, depression and stress disorders.
    Kehne J; De Lombaert S
    Curr Drug Targets CNS Neurol Disord; 2002 Oct; 1(5):467-93. PubMed ID: 12769601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional, endogenously expressed corticotropin-releasing factor receptor type 1 (CRF1) and CRF1 receptor mRNA expression in human neuroblastoma SH-SY5Y cells.
    Schoeffter P; Feuerbach D; Bobirnac I; Gazi L; Longato R
    Fundam Clin Pharmacol; 1999; 13(4):484-9. PubMed ID: 10456290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of CRF
    Tanaka M; Tomimatsu Y; Sakimura K; Ootani Y; Sako Y; Kojima T; Aso K; Yano T; Hirai K
    Peptides; 2017 Sep; 95():40-50. PubMed ID: 28689880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of corticotrophin-releasing factor receptor 1 antagonists on amyloid-β and behavior in Tg2576 mice.
    Dong H; Wang S; Zeng Z; Li F; Montalvo-Ortiz J; Tucker C; Akhtar S; Shi J; Meltzer HY; Rice KC; Csernansky JG
    Psychopharmacology (Berl); 2014 Dec; 231(24):4711-22. PubMed ID: 24862368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ligand affinity for amino-terminal and juxtamembrane domains of the corticotropin releasing factor type I receptor: regulation by G-protein and nonpeptide antagonists.
    Hoare SR; Sullivan SK; Schwarz DA; Ling N; Vale WW; Crowe PD; Grigoriadis DE
    Biochemistry; 2004 Apr; 43(13):3996-4011. PubMed ID: 15049707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of a corticotropin-releasing factor receptor 1 antagonist on the fear conditioning response in low- and high-anxiety rats after chronic corticosterone administration.
    Skórzewska A; Wisłowska-Stanek A; Lehner M; Turzyńska D; Sobolewska A; Krząścik P; Szyndler J; Maciejak P; Płaźnik A
    Stress; 2019 Jan; 22(1):113-122. PubMed ID: 30345859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 125I-Tyro-sauvagine: a novel high affinity radioligand for the pharmacological and biochemical study of human corticotropin-releasing factor 2 alpha receptors.
    Grigoriadis DE; Liu XJ; Vaughn J; Palmer SF; True CD; Vale WW; Ling N; De Souza EB
    Mol Pharmacol; 1996 Sep; 50(3):679-86. PubMed ID: 8794910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anxiolytic-like effects of the corticotropin-releasing factor1 (CRF1) antagonist DMP904 [4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5-a]-pyrimidine] administered acutely or chronically at doses occupying central CRF1 receptors in rats.
    Lelas S; Wong H; Li YW; Heman KL; Ward KA; Zeller KL; Sieracki KK; Polino JL; Godonis HE; Ren SX; Yan XX; Arneric SP; Robertson DW; Hartig PR; Grossman S; Trainor GL; Taub RA; Zaczek R; Gilligan PJ; McElroy JF
    J Pharmacol Exp Ther; 2004 Apr; 309(1):293-302. PubMed ID: 14742750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and synthesis of tricyclic corticotropin-releasing factor-1 antagonists.
    Gross RS; Guo Z; Dyck B; Coon T; Huang CQ; Lowe RF; Marinkovic D; Moorjani M; Nelson J; Zamani-Kord S; Grigoriadis DE; Hoare SR; Crowe PD; Bu JH; Haddach M; McCarthy J; Saunders J; Sullivan R; Chen T; Williams JP
    J Med Chem; 2005 Sep; 48(18):5780-93. PubMed ID: 16134945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Agonist bias and agonist-dependent antagonism at corticotrophin releasing factor receptors.
    Tasma Z; Wills P; Hay DL; Walker CS
    Pharmacol Res Perspect; 2020 Jun; 8(3):e00595. PubMed ID: 32529807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.